2TK.F ELEDON PHARMACEUT.DL-001
- Market cap
- EUR 197M
- P/E
- -
- P/B
- 6.91x
- ROE
- -428.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2TK.F undervalued?
Graham numberThe Graham number of ELEDON PHARMACEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ELEDON PHARMACEUT.DL-001 fundamental analysis
No fundamental analysis for ELEDON PHARMACEUT.DL-001 yet.
ELEDON PHARMACEUT.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ELEDON PHARMACEUT.DL-001
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developin…
Full company profileELEDON PHARMACEUT.DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ELEDON PHARMACEUT.DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -36.9M | -39.8M | -43.0M | -70.6M | -83.3M | -88.1M |
| EBITDA | - | -39.4M | -42.6M | -70.2M | -82.9M | -88.1M |
| Net Income | -34.5M | -88.0M | -117M | -36.2M | -45.6M | -141M |
| EPS | -2.41 | -6.39 | -4.81 | -0.61 | -0.60 | -1.75 |
| Balance Sheet | ||||||
| Total Assets | 171M | 92.8M | 89.1M | 177M | 169M | 126M |
| Total Liabilities | 6.55M | 8.61M | 81.9M | 115M | 87.9M | 93.1M |
| Shareholders' Equity | 164M | 84.2M | 7.21M | 62.4M | 81.1M | 33.0M |
| Cash & Short-term Investments | 84.8M | 56.4M | 4.61M | 20.5M | 22.8M | 6.80M |
| Cash Flow | ||||||
| Operating Cash Flow | -28.9M | -28.4M | -39.5M | -47.3M | -62.3M | -90.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -28.9M | -28.4M | -39.5M | -47.3M | -62.3M | -90.6M |
| Ratios | ||||||
| ROE | -21.0% | -104.5% | -1,616.8% | -57.9% | -56.3% | -428.0% |
| ROA | -20.2% | -94.8% | -130.8% | -20.4% | -27.0% | -112.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ELEDON PHARMACEUT.DL-001 dividends
ELEDON PHARMACEUT.DL-001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:18 on Oct 5, 2020.
Who owns ELEDON PHARMACEUT.DL-001
- Insiders 0.33%
- Institutions 58.98%
- Public & others 40.69%
- Shares outstanding 81.3M
- Free float 74.6M
ELEDON PHARMACEUT.DL-001 company profile
- Company name
- ELEDON PHARMACEUT.DL-001
- Ticker
- 2TK.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 19800 MacArthur Boulevard, Irvine, CA, United States, 92612
- Phone
- 949 238 8090
- Website
- eledon.com
About ELEDON PHARMACEUT.DL-001
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELEDON PHARMACEUT.DL-001 management
8- Dr. David-Alexandre C. Gros M.D., Ph.D.CEO & Non Independent Director · born 1972
- Dr. Steven N. Perrin Ph.D.President, Chief Scientific Officer & Non Independent Director · born 1966
- Mr. Paul Sean LittleChief Financial Officer · born 1965
- Mr. John HerbergerVice President of Technical Operations
- Mr. Bryan E. Smith J.D.General Counsel, Corporate Secretary & Chief Compliance Officer · born 1980
- Dr. David Hovland Ph.D.Chief Regulatory Officer
- Ms. Marina EscuderoVP & Head of Clinical Operations
- Dr. Sepideh HabibiVP and Head of Safety & Pharmacovigilance